linjc16/ctgov huggingface dataset:
Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to evaluate whether the use of indocyanine green fluorescent cholangiography is responsible in a decrease of biliary fistula's rate in patients with liver diseases requiring liver resection.

Official Title
-----------------
Evaluation of Indocyanine Green Fluorescent Cholangiography Versus Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy: Randomized Controlled Study

Conditions
-----------------
Liver Disease

Intervention / Treatment
-----------------
* Procedure: indocyanine green fluorescent cholangiography
* Drug: methylene blue


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: benin or malignant liver disease with resection of 2 or more segments liver resection by laparotomy written consent Exclusion Criteria: previous hepatectomy emergency surgery allergy to indocyanine green allergy to methylene blue pregnancy or breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: indocyanine green fluorescent cholangiography<br>use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed | Procedure: indocyanine green fluorescent cholangiography<br> <br> |
| Active Comparator: methylene blue<br>injection of methylene blue during the surgery | Drug: methylene blue<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| biliary fistula rate | the biliary fistula is defined as a bilirubin in the drain three times higher than the serum bilirubin. the primary endpoint will be evaluated by a medical committee composed by investigators not involved in the patients enrollment. | postoperative week 4 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
per operative cholangiography, liver resection, biliary fistula
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device

Study Overview
=================
Brief Summary
-----------------
The study is performed to collect long-term data on the treatment adherence and patient's acceptability when Zomacton®10 mg is administered with the Zomajet® Vision X device in patients with a growth hormone deficiency or Turner's syndrome.

Conditions
-----------------
Growth Hormone Deficiency, Turner's Syndrome

Intervention / Treatment
-----------------
* Drug: somatropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with growth hormone deficiency, Diagnosis of growth hormone deficiency proven by appropriate exploration Size ≤ -2 Standard Deviation (SD) according to the French references Growth velocity in the previous year inferior to the normal for age (-1SD) or < 4cm/year Growth deficiency due to Turner's syndrome Turner's syndrome confirmed by a karyotype Patient's size ≤ -2 SD according to the French references Bone age < 12 years Patient who require a minimum of 18 months of treatment. Exclusion Criteria: There are no exclusion criteria except the contraindication for Zomacton® 10 mg
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Zomacton® treatment with Zomajet® Vision X device<br> | Drug: somatropin<br> <br> * Other names: Zomacton®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of overall treatment adherence | Ratio between actual duration of administration and total duration recommended by physician | Up to 18 months |
Study of the Clinical Management of Bipolar Disease

Study Overview
=================
Brief Summary
-----------------
This study is to provide reliable information on the management of bipolar disorders in real every day, clinical practice, to determine the clinical outcomes of such management and use of resources in relation to the disease, and to establish the factors associated with different management patterns and clinical outcomes.

Official Title
-----------------
Multinational Ambispective Study of the Clinical Management and Burden of Bipolar Disorder (WAVE bd Study)

Conditions
-----------------
Bipolar Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of Bipolar Disorder I or II (DSM-IV TR) in any phase of the disorder Patients who had at least one mood event (depression, mania, hypomania or mixed) according to DSM-IV TR definition during the 12 months prior to the beginning of the study Exclusion Criteria: Patients who had the index mood event during the 3 months before the beginning of the study (Time 0).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start. | |
| 2<br>Patients diagnosed with Bipolar Disorder I or II (DSM-IV-TR) at any phase of the disorder with at least one mood event during the 12 months before the study start receiving Seroquel extended release at some point during the retrospective period . | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Demographic variables |  | Once during study | 
| 1-year prevalence for each disease phase |  | everytime the patient attends the consult | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Use of resources |  | everytime the patient attends the consult | 
| treatments prescribed, EQ5D |  | everytime the patient attends the consult | 
| treatments prescribed, FAST |  | everytime the patient attends the consult | 
| treatments prescribed, DAI-10 |  | everytime the patient attends the consult | 
| treatments prescribed, MPR |  | everytime the patient attends the consult | 
| treatments prescribed, BAS |  | Once during the prospective part (only if patient attends with a caregiver) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
bipolar disorders, everyday setting, treatment adherence, global
Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HIV-infected patients

Detailed Description
-----------------
Patients meeting the inclusion criteria will be offered to participate to the study. In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activation and inflammatory markers, during the blood test scheduled for the routine follow-up. Six months after cART change, an equal volume of blood will be collected for measuring the same immune activation and inflammatory markers

Official Title
-----------------
Study Aiming to Measure the Impact on Immune Activation and Inflammatory Markers of Switching From a Triple Combination Antiretroviral Therapy (cART) to a Long Acting Dual Therapy in HIV-infected Patients

Conditions
-----------------
HIV-1-infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients agreeing to participate to the study and to collect their data HIV-1 infected subjects Patients switching from a stable (at least 6 months) and successful triple cART to a long acting dual cART Patients older than 18 yrs and regularly followed in Cannes and Nice hospitals Patients with a healthcare card Exclusion Criteria: HIV-2 infected subjects Patients not being on successful and stable cART Patients having being treated during acute HIV-infection Patients modifying cART for virological failure Subjects modifying their treatment for another combination than from a triple cART to a dual cART Patients modifying cART during the 6 months of follow-up Patients refusing to participate to the study Patients included in an interventional study during the 6 months of follwo-up Patient under juridical procedure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evolution the trajectory of immune activation and inflammatory markers | Assess the trajectory of immune activation and inflammatory markers change at 6 month after modifying cART | Baseline and 6 months after modiyfying cART | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prevalence of patients with successful cART | To evaluate prevalence of patients with successful cART (i.e. viral load below 50 copies/ml) 1 month after the switch | 1 month, 3 month, 6 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
inflammatory markers, dual therapy, treatment simplification
Survey of Anesthesiology Residents' Perceptions of Critical Care Medicine as a Career

Study Overview
=================
Brief Summary
-----------------
This study's goal is to investigate the reasons behind the decline in interest in critical care fellowships among anesthesia residents.

Detailed Description
-----------------
Anesthesia-based critical care medicine (CCM) is at a crossroads at the turn of the millennium. Although anesthesiologists were pioneers in the field of critical care, their surgical and pulmonary medicine counterparts have now eclipsed them in terms of both numbers and influence. In the United States, anesthesia-based CCM is a niche specialization of anesthesiology, while in Europe, anesthesiologists play a central role in critical care. Anesthesia-based critical care physician production has remained low on an annual basis. Some medical students join anesthesiology residencies with an interest in critical care training, but this enthusiasm appears to diminish as the number of years of residency grows. In the United States, anesthesiology residents have been unable to fill many critical care fellowship spots consistently. This survey aims to investigate the factors that influence residents' decision to pursue a career as a critical care physician, as it is essential to comprehend the underlying reasons for such a decline.

Official Title
-----------------
Survey of Anesthesiology Residents' Perceptions of Critical Care Medicine as a Career at One Academic Center

Conditions
-----------------
Anesthesia

Intervention / Treatment
-----------------
* Other: Survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anesthesiology residents at Stanford Exclusion Criteria: Non-anesthesiology residents at Stanford

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Anesthesiology residents<br>We plan to distribute a survey to the Stanford anesthesiology residents to investigate the factors that influence residents' decision to pursue a career as a critical care physician. | Other: Survey<br>* There will be no interventions for study participants. Participants will be asked to complete a survey.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decline in applying to CCM fellowships | Examining the declining applying to CCM fellowship whether due to intrinsic factors (i.e., nature of CCM practice) vs extrinsic factors (i.e., job market and relative competing compensation) | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
critical care medicine, fellowship, anesthesiology residency, perception, anesthesia
Greater Occipital Nerve and Cervical Region Injection in Patients With Trigeminal Neuralgia

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to investigate the efficacy of greater occipital nerve block and cervical injections with lidocaine

Detailed Description
-----------------
After being informed about the study and potantiel risks, all patients giving informed consent will undergo randomization in 1:1 ratio to 1% lidocaine or 0.9% saline groups

Official Title
-----------------
Greater Occipital Nerve and Cervical Region Injection in Patients With Trigeminal Neuralgia

Conditions
-----------------
Trigeminal Neuralgia

Intervention / Treatment
-----------------
* Drug: Lidocaine 1% Injectable Solution


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Classical Trigeminal Neuralgia Exclusion Criteria: Secondary Trigeminal Neuralgia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active<br>%1 lidocaine injections to greater occipital nerve and cervical region once a week for 4 weeks | Drug: Lidocaine 1% Injectable Solution<br>* Greater occipital nerve and cervical region injections once a week for 4 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy on pain severity | Efficacy on pain scores. Visual Analogue Scale (VAS). VAS is a ten-point scale where zero refers to no pain and ten refers to maximal pain | 3 months | 
| Efficacy on pain frequency | Pain frequency per day | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Trigeminal Neuralgia, Greater Occipital Nerve Block, Lidocaine
Role of Lung Ultrasound in Confirmation of Correct Double Lumen Endotracheal Tube Placement in Thoracic Surgeries

Study Overview
=================
Brief Summary
-----------------
to assess the efficacy of lung ultrasound versus conventional auscultation method and fiberoptic bronchoscopy in confirmation of double lumen tube position

Detailed Description
-----------------
Confirmation of double lumen tube position by auscultation followed fiberoptic bronchoscopy then lung ultrasound. After double lumen intubation all patient tube position will be confirmed using auscultation then fiberoptic bronchoscopy then lung ultrasound

Official Title
-----------------
Role of Transthoracic Lung Ultrasound in Confirmation of Correct Double Lumen Endotracheal Tube

Conditions
-----------------
Diagnostic Accuracy

Intervention / Treatment
-----------------
* Diagnostic Test: Lung auscultation
* Device: Fiberoptic bronchoscopy
* Device: Lung Ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients scheduled for surgeries under general anesthesia requiring double lumen endotracheal intubation ASA I-II Exclusion Criteria: patient refusal patients not meeting the inclusion criteria

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Lung cancer patients<br>Correct position of double lumen endotracheal tube will be assessed using lung sonography, routine chest auscultation and fiberoptic brochoscopy | Diagnostic Test: Lung auscultation<br>* auscultation of air entry through chest wal<br>Device: Fiberoptic bronchoscopy<br>* Checking correct double lumen position through direct vision using fiberoptic bronchoscopy<br>Device: Lung Ultrasound<br>* real time visualization of air entry to the lungs using trans-thoracic lung ultrasound<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| sensitivity and specificity of lung ultrasound in confirmation of correct double lumen position | real time visulaization of air entry to the lung | 5 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| procedural time | time taken to confirm tube position | 5 minutes |
A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether a new cerebral oxygenation monitoring device is comparatively similar to the current approved devices.

Detailed Description
-----------------
Cerebral oxygenation monitoring is an innovative way to monitoring cardiac surgery patients intraoperatively to reduce the incidence of postoperative hypoxic side effects. There are a number of approved devices already in the market that have proved their efficacy.

Official Title
-----------------
A Prospective Study With a New Device for the Monitoring of Cerebral Oxygenation on Cardiac Surgery Patients

Conditions
-----------------
Coronary Artery Disease, Heart Valve Disease

Intervention / Treatment
-----------------
* Device: CDI 1000 COM and INVOS 5100


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be 18 years old or older Scheduled for cardiac surgery Treatment will include 72 hours or more of hospital stay Understand enough about the risks and benefits of the study to be able to make an informed decision before agreeing to be in the study Exclusion Criteria: History of cerebrovascular disease History of skin problems on forehead (skin rashes, acne, allergies, etc.) History of craniofacial surgeries Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiac Surgery or Hospitalization<br>Patients scheduled for a Cardiac Surgery procedure, two types of cerebral oximetry devices were compared at the same time during the surgical procedure. The second group were patients hospitalized (in the Intensive Care Unit or ICU, with any diagnosis, excluding head trauma patients. Those patients were monitored using two types of cerebral oximetry devices at the same time for up to 72 hours. | Device: CDI 1000 COM and INVOS 5100<br>* CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.<br>* Other names: Somanetics INVOS 5100;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To test a new device for Cerebral Oxygenation Monitoring |  | 12 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety of human forehead skin during period of probe adhesion |  | 12 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypoxia, Cerebral Hypoxia
Evaluation of the PlasmaJet Neutral Argon Plasma System to Treat Skin Ageing

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the comparative effects of the PlasmaJet neutral argon plasma system and the Rhytec Portrait PRS nitrogen plasma system in the treatment of aging facial skin

Official Title
-----------------
Evaluation of the PlasmaJet Neutral Argon Plasma System for Skin Regeneration and Comparison With the Rhytec Portrait PSR Plasma System

Conditions
-----------------
Skin Aging

Intervention / Treatment
-----------------
* Procedure: Exposure to plasma energy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: request for treatment to improve facial skin Exclusion Criteria: pregnancy history of HIV infection autoimmune or connective tissue disorder

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Skin treatment<br> | Procedure: Exposure to plasma energy<br>* Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of skin appearance and condition by photography and digital image analysis |  | At intervals for up to 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of skin condition and dermal architecture by ultrasound imaging |  | At intervals for up to 12 months | 
| Assessment of skin elasticity by non-invasive means |  | At intervals for up to 12 months | 
| Assessment of pain during treatment |  | During treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Skin aging, Skin wrinkling